Sector News

Merck KGaA’s deputy chief Oschmann set to become CEO – Manager Magazin

March 20, 2015
Life sciences
(Reuters) – Germany’s Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.
 
The publication said Oschmann, 57, would take on the new role after the group’s annual shareholder meeting in April 2016 or in September next year at the latest, when Kley’s current contract expires.
 
The German drugs and chemicals maker last September appointed Oschmann, the head of its pharma business at the time, as deputy chief executive from January, sharing strategic management functions and representation of the company with Kley, who is 63.
 
A Merck spokeswoman said a decision on Kley’s succession has not yet been made and that this would be a matter for the family-controlled group’s board of partners. She declined to comment further.
 
Merck, which is also the world’s largest maker of liquid crystals for flat-panel displays, is buying Sigma-Aldrich , putting it on track to become the world’s second-largest lab supplies maker after Thermo Fisher.
 
Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc’s emerging markets operations. The two companies share historic roots but are under separate ownership since World War One. (Reporting by Georgina Prodhan; Editing by Ludwig Burger and Greg Mahlich)

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).